<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111067">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056665</url>
  </required_header>
  <id_info>
    <org_study_id>A-MANECE</org_study_id>
    <nct_id>NCT02056665</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome</brief_title>
  <acronym>A-MANECE</acronym>
  <official_title>Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF
      MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Increased on the equivalent age of development</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increased on the equivalent age of development, obtained through Development Scale R Merrill-Palmer (MP-R)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved specific cognitive, language and communication, motor development, social-emotional and adaptive behavior</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improved specific cognitive, language and communication, motor development, social-emotional and adaptive behavior obtained through Development Scale R Merrill-Palmer (MP-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of EEG.</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of EEG. Measure based on changes in the background activity, type, number and duration of crises, widespread tendency to crises, paroxysmal abnormalities recorded types and the overall evaluation of clinical neurophysiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>a) Physical Examination b) Vital signs c) Laboratory Tests d) Adverse effects (AEs) list for treatment, laboratory values, values outside the reference range and descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global impression (CGI)</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of CGI. . Measure based on changes in the Clinical Global Impression through the perception of parents or guardians, you neurologists and therapist</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>MINOCYCLINE 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of treatment: 8 weeks
Patients &lt;35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
Patients &gt; 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO 8 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pill manufactured to mimic Minocycline 50 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MINOCYCLINE 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of treatment: 16 weeks
Patients &lt;35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
Patients &gt; 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MINOCYCLINE</intervention_name>
    <arm_group_label>MINOCYCLINE 8 weeks</arm_group_label>
    <arm_group_label>PLACEBO 8 weeks</arm_group_label>
    <arm_group_label>MINOCYCLINE 16 weeks</arm_group_label>
    <other_name>Commercial name: Aknemin 50</other_name>
    <other_name>Active substance:  MINOCYCLINE</other_name>
    <other_name>Administration routes:  Oral use</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO (for Minocycline)</intervention_name>
    <description>Pill manufactured to mimic Minocycline 50 mg capsule</description>
    <arm_group_label>MINOCYCLINE 8 weeks</arm_group_label>
    <arm_group_label>PLACEBO 8 weeks</arm_group_label>
    <other_name>Commercial name: NA</other_name>
    <other_name>Non Active substance:</other_name>
    <other_name>Administration routes: Oral use</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 6 and 30 years old.

          -  Clinical diagnosis of Angelman Syndrome and molecular confirmation of diagnosis.

          -  The participant has an acceptable guardian can give consent on behalf of the
             participant.

        Exclusion Criteria:

          -  Patients with hypersensitivity to tetracyclines.

          -  Patients with impaired hepatic or renal function and in those with mainly drug
             allergy history.

          -  Any other condition that in the opinion of the investigator is considered clinically
             relevant and that administration of minocycline contraindicated
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belen Ruiz-Antorán</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology. Puerta de Hierro University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Belen Ruiz-Antoran</last_name>
    <phone>34911917479</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Puerta de Hierro University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Ruiz-Antoran</last_name>
      <phone>34911917479</phone>
      <email>mariabelen.ruiz@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Belen Ruiz-Antorán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>BELEN RUIZ-ANTORAN</investigator_full_name>
    <investigator_title>DR</investigator_title>
  </responsible_party>
  <keyword>Angelman Syndrome</keyword>
  <keyword>EFFICACY</keyword>
  <keyword>SAFETY</keyword>
  <keyword>MINOCYCLINE</keyword>
  <keyword>Pediatrics population</keyword>
  <keyword>Rare diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angelman Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
